Study Shows How Ocd Adhd Parkinsons And Psychosis Are Related
August 8, 2016 by Dr. Carlo
Picture the person with OCD he spends hours washing, and can literally be stuck in the shower or sink. Now picture the person with ADHD he frequently flips from one activity to the next, just a constant stream of motion, and unable to do the same movement for very long. So one spends all their time in one place in rituals, while the other impulsively flips to various activity, unable to sustain attention. These two disorders appear to be different, but they are related with regards to the lack of control of their movements .
In addition, there are other neuropsychiatric disorders which have problems with the lack of control of movements , including Parkinsons, Tourettes, Huntingtons, and psychosis. What is interesting is that all of these disorders are linked to dysfunctions of the basal ganglia, which mediates movement in the brain.
A new study has revealed that OCD may be triggered by the activation of the direct pathway in the basal ganglia, while ADHD is triggered by the disruption of the indirect pathway of the basal ganglia. These two pathways were previously studied in isolation, but they appear to work simultaneously to help us control our actions.
If you look at OCD, ADHD, Parkinsons disease, and psychosis, they all involve problems with the control of movement :
Adhd & Pd: The Basal Ganglia And Cerebellum Connection
All Science News articles summarize a research study and are not an official opinion, endorsement or position of the Parkinsons Foundations.
Two parts within our brain require healthy dopamine regulation and transmission to do their jobs:
- The basal ganglia: messengers that sort out information for the spinal cord and cerebellum and are associated with various functions, including motor control, motor learning, executive functions and behaviors, and emotions.
- The cerebellum: involved in movement and coordination, walking, posture, reflexes, and eye and head movement it also sends instructions to our muscles that adjusts our posture and keeps our bodies moving smoothly.
Adults with attention-deficit hyperactivity disorder have been shown to have damaged dopamine neurons in the basil ganglia, and, commonly have cerebellar abnormalities, much like people with Parkinsons disease . So, are ADHD and PD somehow connected? Perhaps.
A recently published study in the journal, Neuropsychopharmacology, sought to determine if having ADHD and/or its treatment, increases the risk of having basal ganglia and cerebellar diseases. In this 20-year follow-up retrospective cohort study, a total of 190,586 patient records from Utah were examined. People with no prior PD diagnosis or symptoms, no basal ganglia/cerebellar disease and those with a history of substance abuse were excluded from participating in the study.
In terms of comparing people with ADHD to non-ADHD, :
Representativeness Of Patient Samples
In a smaller case control study , participants were identified as positive cases of ADHD if they demonstrated both current and childhood symptoms. As a result, cases of remitted ADHDgenerally thought to represent at least 5060% of ADHD cases were unaccounted for. It is unclear if or how the dementia and control groups differed in their prevalence of remitted ADHD, but this has important implications for understanding relationships between ADHD in early life and later neurodegenerative disease risk. Notably, prevalence of ADHD in this study was roughly five times higher in the control group relative to expected frequencies of ADHD in the general adult or older adult population , strongly implying faulty recall and/or an unrepresentative sample.
You May Like: Sam Waterston Parkinson’s
Medications That Increase Dopamine
Many medications for treating ADHD work by increasing dopamine and stimulating focus. These medications are typically stimulants. They include amphetamines such as:
These medications increase dopamine levels in the brain by targeting dopamine transporters and increasing dopamine levels.
Some people believe that taking a high dosage of these medications will lead to greater focus and attention. This is not true. If your dopamine levels are too high, this can make it difficult to focus.
Using Amphetamines May Increase Risk Of Parkinsons Disease
The American Academy of Neurology, an association of more than 22,500 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimers disease, stroke, migraine, multiple sclerosis, brain injury, epilepsy and Parkinsons disease.For more information about the American Academy of Neurology and its upcoming Annual Meeting, visit .
Recommended Reading: Pfnca Wellness Programs
New Research Finds Link Between Adhd And Parkinson Disease
Researchers from the University of Utah explain that patients with attention-deficit/hyperactivity disorder were more than twice as likely to develop early-onset Parkinson disease or a related basal ganglia and cerebellum disease than peers who do not have ADHD. Among patients with more severe disease who are prescribed stimulant medications to control their ADHD, the risk was 6- to 8-fold higher.
Attention-deficit/hyperactivity disorder affects approximately 11% of children in the United States, and some previous research has suggested that that exposure to stimulants commonly used to treat the disorder can result in persistent basal ganglia dopaminergic deficits. Now, new research shows that patients with ADHD have an increased risk of developing Parkinson disease and related basal ganglia and cerebellum diseases, and patients treated with stimulants have an even greater risk.
In a paper today in Neuropsychopharmacology, researchers from the University of Utah explain that patients with ADHD were more than twice as likely to develop early-onset PD or a BGC disease than peers who do not have ADHD. Among patients with more severe disease who are prescribed stimulant medications to control their ADHD, the risk was 6- to 8-fold higher.
In the ADHD cohort, the rate of incident BGC diseases was 0.52%, compared with 0.19% in the non-ADHD cohort, and the age of disease onset was slightly younger among patients with ADHD than in those without ADHD .
Adhd And Neurodegenerative Disease Risk: A Critical Examination Of The Evidence
- 1Department of Psychology, University of Calgary, Calgary, AB, Canada
- 2Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada
In this review, we undertake a critical appraisal of eight published studies providing first evidence that a history of attention-deficit/hyperactivity disorder may increase risk for the later-life development of a neurodegenerative disease, in particular Lewy body diseases , by up to five-fold. Most of these studies have used data linked to health records in large population registers and include impressive sample sizes and adequate follow-up periods. We identify a number of methodological limitations as well, including potential diagnostic inaccuracies arising from the use of electronic health records, biases in the measurement of ADHD status and symptoms, and concerns surrounding the representativeness of ADHD and LBD cohorts. Consequently, previously reported risk associations may have been underestimated due to the high likelihood of potentially missed ADHD cases in groups used as controls, or alternatively previous estimates may be inflated due to the inclusion of confounding comorbidities or non-ADHD cases within exposed groups that may have better accounted for dementia risk. Prospective longitudinal studies involving well-characterized cases and controls are recommended to provide some reassurance about the validity of neurodegenerative risk estimates in ADHD.
Read Also: Diseases Similar To Parkinsons
Parkinson Disease And Adhd: Whats The Connection
Attention-deficit/hyperactivity disorder involves dysregulated dopaminergic pathways, and as such, dopaminergic agents such as amphetamine and methylphenidate are prescribed to treat the condition. Because little is known about the long-term consequences of either ADHD or its treatment, researchers designed a retrospective cohort study to determine if either affects the risk of diseases of the basal ganglia and cerebellum, including Parkinson disease .
Using statewide Utah medical records from 1996 to 2016, the authors identified 31,769 adult patients with a diagnosis of ADHD and 158,790 random sex-matched and age-matched patients without an ADHD diagnosis. The participants had no history of PD or parkinsonian diseases, basal ganglia diseases, essential tremor, or substance abuse. The outcomes measures were time to diagnosis of basal ganglia and cerebellum diseases or death.
The findings showed that patients with ADHD had a 2.4-fold increased risk of basal ganglia and cerebellum diseases than control participants after controlling for sex, age, tobacco use, and psychotic conditions. They found that the 4960 ADHD patients who had been prescribed psychostimulants had an 8.6-fold higher risk of developing Parkinson-like diseases between the ages of 21 and 49.
What Does The New Study Show
The study, published Wednesday in Neuropsychopharmacology, found that people with ADHD seemed to have a risk of developing Parkinsons disease or Parkinsons-like diseases.
Parkinsons disease, a movement disorder typically seen in elderly people, is thought to result from a loss of dopamine a neurotransmitter responsible for regulating movement in the brain.
Don’t Miss: Fitflop Shoes For Parkinson’s
Balance Of Strengths And Weaknesses
We conducted a formal evaluation of the quality of the eight studies in this review using the Newcastle-Ottawa Scale , and found many strengths across each . All case-control studies had clear criteria for the selection of controls, and two ensured that participants were age- and sex-matched . Consensus criteria were used in two of the three case-control studies to ascertain neurodegenerative disease outcomes . Among cohort studies, strengths included participants drawn from large population cohorts and usually matched on age and sex . Follow-up length was at least 10 years in four studies .
Table 2. Evaluation of the quality of the eight studies in this review using the Newcastle-Ottawa Scale.
Schizophrenia Parkinsons Disease And Attention Deficit Hyperactivity Disorder
- Chapter 9 Schizophrenia, Parkinsons disease, and attention deficit hyperactivity disorder
- Oxford University Press
Schizophrenia, Parkinsons disease, and attention deficit hyperactivity disorder discusses how hyperactive dopaminergic neurotransmission appears to underlie schizophrenias positive symptoms, loss of dopaminergic neurons in adulthood leads to Parkinsons disease, and dopamine neuron hypofunction in childhood and adolescence may underlie ADHD. Positive schizophrenia symptoms may arise from excessive incentive learning that is gradually lost with antipsychotic treatment. Declarative learning and memory may contribute to delusions based on excessive incentive learning. Loss of responsiveness to environmental stimuli in Parkinsons may result from a decrease of their conditioned incentive value and inverse incentive learning. Conditioned incentive stimuli not encountered while in a state of decreased dopaminergic neurotransmission may retain their incentive value, producing apparent kinesia paradoxa. Dopamine hypofunction in juveniles does not lead to hypokinesia but may result in loss of incentive learning that focuses attention. Pro-dopaminergic drugs have a calming effect in ADHD, presumably because they reinstate normal incentive learning.
Please, or to access full text content.
If you think you should have access to this title, please contact your librarian.
You May Like: Does Vitamin B12 Help Parkinson’s
Methylphenidate And Parkinson’s Disease
Parkinson’s disease is a common disorder caused by the loss of dopamine-producing brain cells. The disorder is generally treated with levodopa combined with carbidopa. Nerve cells use levodopa to make dopamine. Carbidopa delays the conversion of levodopa into dopamine until it reaches the brain. Motor fluctuations are a common, and often difficult to manage, source of disability in people with PD. In this trial researchers will study the effects of methylphenidate , also known as Ritalin-a drug marketed in the U.S. to treat hyperactivity and narcolepsy-on carbidopa/levodopa and other antiparkinson medications taken orally by individuals with Parkinson’s disease who experience motor fluctuations when they take levodopa. The overall goal of this project is to develop better symptomatic therapies for PD. After 2 screening visits to the treatment clinic to evaluate the wearing “on” and “off” effects of levodopa, eligible participants will be scheduled for 3 admissions to the GeneralClinical Research Center at Oregon Health & Science University during which they randomly will receive the study drug, MPD, or placebo, along with their usual carbidopa/levodopa therapy and/or other antiparkinson medications. Also, participants will have their parkinsonism rated and blood pressure and pulse measured at regular intervals. Duration of the study for participants is about 3 weeks and includes 2 outpatient clinic visits and 3 inpatient clinic visits .
Adhd Diagnosis Could Increase Risk For Parkinsons Study Suggests
People diagnosed with attention deficit/hyperactivity disorder , usually detected at an early age in hyperactive children, may have an increased risk of developing Parkinsons and Parkinsons-like diseases, a new study suggests.
Parkinsons disease is commonly thought of as a neurodegenerative disease associated with aging, Glen Hanson, PhD, professor at the University of Utah Health and the studys lead author, said in a press release. This may be the first time where a childhood disease and its treatment may be linked to a geriatric expression of neurodegenerative disorder.
The study, Increased Risk of Diseases of the Basal Ganglia and Cerebellum in Patients with a History of Attention-Deficit/Hyperactivity Disorder, was published in the journal Neuropsychopharmacology.
ADHD is estimated to affect approximately 11% of children ages 4-7 in the United States, according to data from the Centers for Disease Control and Prevention .
ADHD, characterized by hyperactivity and attention impairments that may interfere with the childs development, is linked with a deregulated release of the neurotransmitter dopamine, a key signaling molecule that regulates brain cell activity and function.
Read Also: Judy Woodruff Health Problems
Outcome Of Diseases Of The Basal Ganglia And Cerebellum
We measured time from baseline to an index diagnosis on or before 31 December 2016 of any adult-onset diseases of the basal ganglia and cerebellum including Parkinsons disease, secondary parkinsonism, other degenerative diseases of the basal ganglia, and essential tremor based on ICD-9 codes . Hereafter, diseases of the basal ganglia and cerebellum are referred to as BG& C diseases. Right censoring occurs when a subject dies, is lost to follow-up, or the study ends before an outcome is observed. Study subjects with no diagnosis of BG& C diseases who died on or before 31 December 2016 were treated as having a competing cause of death and right censored at their death date. Subjects alive on 31 December 2016 who did not develop BG& C diseases were right censored.
Adhd Medication Linked With Higher Risk For Parkinsons Disease
We were unable to process your request. Please try again later. If you continue to have this issue please contact .Glen R. Hanson
Patients with ADHD who were treated with amphetamine- or methylphenidate-based medications may be at higher risk for basal ganglia and cerebellum disorders such as Parkinsons disease, secondary parkinsonism or essential tremor later in life, according to findings recently published in Neuropsychopharmacology.
Little is known about the effects of long-term, therapeutic use of psychostimulants such as that associated with treatment of ADHD, researchers wrote.
They looked at data from 31,769 patients diagnosed with ADHD, of whom 4,960 had been prescribed mixed amphetamine salts , methylphenidate , or both . These patients were then matched with 158,790 patients without ADHD.
Researchers found all patients with ADHD had a 2.4-fold increased risk for Parkinsons disease, secondary parkinsonism or essential tremor vs. the patients without ADHD after controlling for age, sex, psychotic conditions and tobacco use. In addition, the 4,960 patients with ADHD who had been prescribed amphetamine- or methylphenidate-based psychostimulants had an 8.6-fold increased risk for Parkinsons disease, secondary parkinsonism or essential tremor.
Our calculations likely underestimate the total impact of ADHD on the risk for developing diseases, especially in younger populations, they added.
Disclosures:The authors report no relevant financial disclosures.
Don’t Miss: Similar To Parkinsons
What’s An Adhd Drug Got To Do With Parkinsons
Atomoxetine works by boosting and rebalancing the levels of a chemical called noradrenaline in the brain.
Noradrenaline plays a role in processing thoughts and behaviour. In Parkinsons, an imbalance can lead to changes in thinking and processing of actions. The extent of this chemical imbalance and subsequent impact can vary from person to person.
Previous research has shown atomoxetine could help treat impulsiveness and cognitive decline in some people with Parkinsons. But there was no easy way to identify individuals who might benefit most from this treatment.
Possible Link Between Adhd And Parkinson’s Found
A study out of the University of Utah has concluded that ADHD may increase the risk of Parkinson’s.
The team found ADHD patients were more than twice as likely to develop early onset Parkinson’s and Parkinson-like diseases compared to non-ADHD individuals of the same gender and age.
The estimated risk was 6 to 8-times higher for those prescribed the stimulant medications. The results are available online from 12 September in the journal Neuropsychopharmacology.
Adhd May Increase Risk Of Parkinson’s Disease And Similar Disorders
- University of Utah Health
- Researchers have found that ADHD patients had an increased risk of developing Parkinson’s and Parkinson-like diseases than individuals with no ADHD history.
While about 11 percent of children nationwide have been diagnosed with attention-deficit hyperactivity disorder , the long-term health effects of having ADHD and of common ADHD medications remains understudied. Researchers at University of Utah Health found that ADHD patients had an increased risk of developing Parkinson’s and Parkinson-like diseases than individuals with no ADHD history. The results are available online on September 12 in the journal Neuropsychopharmacology.
“Parkinson’s disease is commonly thought of as a neurodegenerative disease associated with aging,” said Glen Hanson, D.D.S., Ph.D., professor of Pharmacology and Toxicology and School of Dentistry at U of U Health and senior author on the paper. “This may be the first time where a childhood disease and its treatment may be linked to a geriatric expression of neurodegenerative disorder.”
In a retrospective, population-based study, Hanson’s team found ADHD patients were more than twice as likely to develop early onset Parkinson’s and Parkinson-like diseases compared to non-ADHD individuals of the same gender and age. The estimated risk was six to eight-times higher for ADHD patients prescribed the stimulant medications, including methylphenidate , mixed amphetamine salts and dexmethylphenidate .